Replies to post #1883 on Fresenius Kabi Pharmaceuticals (APCVZ)

[sigma_x]

I Have the Answer You're ALL Looking For... Just got off the phone with IR at APP Pharma - a lovely sounding young woman named Christine Cassiano - and I asked her, point blank, if KF Oncology was the same as APP Pharma, and the answer was no....

HOWEVER (& this is where it gets tricky)...

Any drug approved for KF Oncology, of KF, or whoever, that is going to be marketed in the US, is going to be sold by APP Pharma. So any EBITDA that would show up as a result of sales in the US will show up in relation to the CVR's.

So there you have it. There's competition for these drugs, of course, but APP Pharma will get the rev on their books for anything sold in the U.S.

So figure out what the U.S. market is for these two drugs, figure out a conservative estimate for what APP might be able to hone in on, and - et voila - you can get an idea of whether or not they'll make the remaining $531 mln in the next 3 qtrs.

See, that was easy.